Research programme: diagnostic tracer agents - MediBeacon

Drug Profile

Research programme: diagnostic tracer agents - MediBeacon

Alternative Names: MB-112; MB-202; MB-212; MB-301; MB-402

Latest Information Update: 24 Jan 2017

Price : $50

At a glance

  • Originator MediBeacon
  • Class Diagnostic agents; Imaging agents
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Kidney disorders
  • Research Gastrointestinal disorders; Unspecified

Most Recent Events

  • 24 Jan 2017 Early research in Undefined indication (Diagnosis) in USA (Parenteral) before January 2017
  • 12 Oct 2016 Early research in Gastrointestinal disorders (Diagnosis) in USA (Parenteral) before October 2016 (MediBeacon pipeline, October 2016)
  • 12 Oct 2016 Preclinical trials in Kidney disorders (Diagnosis) in USA (Parenteral) before October 2016 (MediBeacon pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top